OTTAWA, Feb. 28 /CNW/ - Liponex Inc. (TSX: LPX), a biopharmaceutical company specializing in developing advanced products related to High Density Lipoprotein (HDL), often called “good cholesterol,” today announced that it has received Health Canada approval to initiate a clinical trial in a patient population using a new formulation of its lead pharmaceutical product, CRD5, being developed for the treatment and prevention of heart disease.
